Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating adverse events and changes in disease activity comparing oral upadacitinib with subcutaneous dupilumab in children aged 2 to less tha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: RECRUITING